Patents Assigned to Dandrit Biotech A/S
  • MICRO RNAS AS MARKERS OF THE FUNCTIONAL STATE OF A DENDRITIC CELL
    Publication number: 20100266555
    Abstract: The present invention relates to the use of specified micro RNAs as markers of the functional state of a dendritic cell. In one aspect the invention relates to a method for producing a quality-controlled therapeutic composition comprising dendritic cells. In another aspect the invention relates to a method of in vitro screening of immunomodulatory compounds.
    Type: Application
    Filed: November 14, 2008
    Publication date: October 21, 2010
    Applicants: DANDRIT BIOTECH A/S, BIONEER A/S
    Inventors: Simon Skjøde Jensen, Kim Holmstrøm, Ayako Wakatsuki Pedersen, Mai-Britt Zocca
  • METHOD FOR GENERATING TOLEROGENIC DENDRITIC CELLS EMPLOYING DECREASED TEMPERATURE
    Publication number: 20100233197
    Abstract: The invention relates in certain embodiments to a method for generating tolerogenic dendritic cells by employing temperatures below 37° C. and phenotype-modifying agents during the development of progenitor cells and immature dendritic cells. In some embodiments the invention relates to populations of dendritic cells and their use.
    Type: Application
    Filed: November 13, 2008
    Publication date: September 16, 2010
    Applicant: DANDRIT BIOTECH A/S
    Inventors: Ayako Wakatsuki Pedersen, Mai-Britt Zocca
  • Pharmaceutical composition for inducing an immune response in a human or animal
    Patent number: 7771998
    Abstract: The present invention relates to a pharmaceutical composition for inducing an immune response in a human or animal, comprising dendritic cells loaded with at least five cancer/testis antigen and no lineage specific differentiation antigens or substantially no lineage specific differentiation antigens provided from at least one cancer cell line, as well as to isolated cell lines expressing a multiplicity of cancer testis antigens and no differentiation antigens, and to a method of inducing an immune response in a human or animal using the composition of the invention.
    Type: Grant
    Filed: November 29, 2002
    Date of Patent: August 10, 2010
    Assignee: Dandrit Biotech A/S
    Inventors: Alexei Kirkin, Karine Djandjougazian, Jesper Zeuthen
  • Pharmaceutical composition for inducing an immune response in a human or animal
    Patent number: 7723107
    Abstract: The present invention relates to a pharmaceutical composition for inducing an immune response in a human or animal, comprising dendritic cells loaded with at least five cancer/testis antigen and no lineage specific differentiation antigens or substantially no lineage specific differentiation antigens provided from at least one cancer cell line, as well as to isolated cell lines expressing a multiplicity of cancer testis antigens and no differentiation antigens, and to a method of inducing an immune response in a human or animal using the composition of the invention.
    Type: Grant
    Filed: July 29, 2008
    Date of Patent: May 25, 2010
    Assignee: Dandrit Biotech A/S
    Inventors: Alexei Kirkin, Karine Djandjougazian, Jesper Zeuthen
  • Method for Generating Dendritic Cells Employing Decreased Temperature
    Publication number: 20090196856
    Abstract: The invention relates in certain embodiments to a method for generating dendritic cells by employing temperatures below 37° C. during the development of progenitor cells and immature dendritic cells. In some embodiments the invention relates to populations of dendritic cells and its use.
    Type: Application
    Filed: December 7, 2006
    Publication date: August 6, 2009
    Applicant: DanDrit Biotech A/S
    Inventors: Alexei Kirkin, Karine Djandjougazian, Jesper Zeuthen
  • PHARMACEUTICAL COMPOSITION FOR INDUCING AN IMMUNE RESPONSE IN A HUMAN OR ANIMAL
    Publication number: 20090029457
    Abstract: The present invention relates to a pharmaceutical composition for inducing an immune response in a human or animal, comprising dendritic cells loaded with at least five cancer/testis antigen and no lineage specific differentiation antigens or substantially no lineage specific differentiation antigens provided from at least one cancer cell line, as well as to isolated cell lines expressing a multiplicity of cancer testis antigens and no differentiation antigens, and to a method of inducing an immune response in a human or animal using the composition of the invention.
    Type: Application
    Filed: July 29, 2008
    Publication date: January 29, 2009
    Applicant: DANDRIT BIOTECH A/S
    Inventors: Alexei KIRKIN, Karine Djandjougazian, Jesper Zeuthen